Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 40

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 40
---
Edesa Biotech, Inc.

Condensed Interim Consolidated Balance Sheets

			June 30, 2025

			September 30, 2024

			Assets:

			Current assets:

			Cash and cash equivalents

			$
			12,361,690

			$
			1,037,320

			Accounts and other receivable

			286,743

			270,908

			Prepaid expenses and other current assets

			112,659

			367,394

			Total current assets

			12,761,092

			1,675,622

			Non-current assets:

			Long-term deposits

			40,739

			41,151

			Intangible asset, net

			2,002,969

			2,078,848

			Right-of-use assets

			-

			18,361

			Total assets

			$
			14,804,800

			$
			3,813,982

			Liabilities and shareholders' equity:

			Current liabilities:

			Accounts payable and accrued liabilities

			$
			672,674

			$
			1,812,960

			Short-term right-of-use lease liabilities

			-

			19,867

			Total current liabilities

			672,674

			1,832,827

			Shareholders' equity:

			Capital shares

			Authorized unlimited common shares without par value

			Issued and outstanding:

			7,022,678 common shares (September 30, 2024 - 3,247,389)

			54,271,112

			47,236,024

			Authorized preferred shares issued and outstanding

			150 Series A-1 preferred shares (September 30, 2024 - 0)

			1,054,735

			-

			834 Series B-1 preferred shares (September 30, 2024 - 0)

			8,168,063

			-

			Additional paid-in capital

			14,406,511

			13,576,757

			Accumulated other comprehensive loss

			(123,077
			)

			(242,613
			)

			Accumulated deficit